ABRACL

Across TCGA pan-cancer cohorts, ABRACL RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ABRACL data layer compared with 1 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ABRACL RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ABRACL expression acts as an unfavorable survival marker, although some lineages such as BLCA and READ show a favorable association.

ESCA, BLCA, and ACC are the cancer types where ABRACL RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.420	0.672	<.001	123	view →
BLCA	OS	Median	All	0.557	0.308	<.001	120	view →
ACC	DFS	Tertile	All	0.372	0.889	<.001	80	view →
LGG	OS	Median	All	0.722	0.894	<.001	54	view →
BRCA	OS	Median	II,III,IV	0.885	0.938	.004	37	view →
UCS	DFS	Tertile	II,III,IV	0.270	0.627	.012	36	view →
OV	DFS	Median	II,III,IV	0.339	0.420	.009	32	view →
READ	DFS	Median	II,III,IV	0.926	0.299	<.001	32	view →
HNSC	OS	Median	All	0.450	0.740	<.001	31	view →
KIRC	OS	Median	All	0.835	0.923	.001	28	view →
STAD	DFS	Median	IV	0.171	0.490	.017	27	view →
CHOL	DFS	Median	All	0.640	0.197	.016	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

ABRACL–ESCA (OS)

Open the ESCA breakdown →